Tetrahydromagnolol (THM) is a hydrogenated derivative of Magnolol. That transformation changes its target: where Magnolol works primarily on GABA, THM becomes active on the endocannabinoid system — the network the body uses to regulate pain, mood and nervous wind-down.
The scientific mechanism THM behaves as a cannabinoid receptor agonist, with marked affinity for CB2 (peripheral, immune) and activity at CB1 (central). It also retains part of the GABA-A modulation inherited from Magnolol. This dual entry point — endocannabinoid and GABAergic — is what sets it apart from classic plant relaxants.
What the data says — and what it does not Let us be direct, because this is the part that matters. THM is a recent molecule: its pharmacology is published, but human clinical data is near non-existent. It is not a traditional extract like Magnolol, it is a semi-synthetic derivative. We offer it to informed users who know what they are testing — not as a first-line product. If you are new to this family, start with Magnolol.
Specific precautions CB1 activity implies possible central effects. Do not drive or operate machinery after taking it. No combination with alcohol, sedatives or anxiolytics. Start with half a capsule, one evening, at home, to gauge your sensitivity.
Quality & Transparency Commitment Tetrahydromagnolol, HPLC purity >98%, 400 mg per capsule. Single-ingredient, no bulking excipients. HPMC vegetal capsule.
